ABCL635

August 10, 2026: AbCellera (NASDAQ: ABCL) reported positive topline Phase 2 results from its Phase 1/2 trial of ABCL635, an investigational NK3R antagonist antibody for moderate-to-severe vasomotor symptoms (hot flashes) due to menopause. In the randomized, double-blind, placebo-controlled study, 92 postmenopausal women received a single subcutaneous 600 mg dose of ABCL635 or placebo.

The trial met its primary efficacy endpoints, showing statistically significant reductions in both frequency and severity of moderate-to-severe vasomotor symptoms at week 4 versus placebo, with significance maintained from week 1 through week 4 (p<0.001). At week 4, ABCL635 reduced symptom frequency by 8.8 events/day from baseline versus 3.5 for placebo, a placebo-adjusted difference of 5.3; percent reduction was 83% versus 33%. Severity improved by 1.4 points versus 0.3 for placebo, a placebo-adjusted difference of 1.1; percent reduction was 58% versus 12%. The company also said ABCL635 significantly improved sleep and patient global impression of change.

ABCL635 was reported as well tolerated over four weeks, with no serious or severe adverse events and no discontinuations; common adverse events above placebo were headache, fatigue, and injection-site reaction. AbCellera said it would host an investor call on August 10, 2026.